WO2005039574A8 - 角結膜障害の治療剤 - Google Patents

角結膜障害の治療剤

Info

Publication number
WO2005039574A8
WO2005039574A8 PCT/JP2004/016063 JP2004016063W WO2005039574A8 WO 2005039574 A8 WO2005039574 A8 WO 2005039574A8 JP 2004016063 W JP2004016063 W JP 2004016063W WO 2005039574 A8 WO2005039574 A8 WO 2005039574A8
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agent
corneal
benzoimidazol
ylmethoxy
thiazolidine
Prior art date
Application number
PCT/JP2004/016063
Other languages
English (en)
French (fr)
Other versions
WO2005039574A1 (ja
Inventor
Masatsugu Nakamura
Shin-Ichiro Hirai
Original Assignee
Santen Pharmaceutical Co Ltd
Masatsugu Nakamura
Shin-Ichiro Hirai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd, Masatsugu Nakamura, Shin-Ichiro Hirai filed Critical Santen Pharmaceutical Co Ltd
Priority to CA2543452A priority Critical patent/CA2543452C/en
Priority to SI200431607T priority patent/SI1679074T1/sl
Priority to AT04793171T priority patent/ATE490771T1/de
Priority to DK04793171.2T priority patent/DK1679074T3/da
Priority to EP04793171A priority patent/EP1679074B1/en
Priority to CN2004800309819A priority patent/CN1870997B/zh
Priority to PL04793171T priority patent/PL1679074T3/pl
Priority to KR1020067009936A priority patent/KR101154175B1/ko
Priority to DE602004030470T priority patent/DE602004030470D1/de
Priority to US10/576,719 priority patent/US7358255B2/en
Publication of WO2005039574A1 publication Critical patent/WO2005039574A1/ja
Publication of WO2005039574A8 publication Critical patent/WO2005039574A8/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/JP2004/016063 2003-10-24 2004-10-22 角結膜障害の治療剤 WO2005039574A1 (ja)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA2543452A CA2543452C (en) 2003-10-24 2004-10-22 Therapeutic agent for keratoconjunctival disorder
SI200431607T SI1679074T1 (sl) 2003-10-24 2004-10-22 Terapevtsko sredstvo za keratokonjuktivno motnjo
AT04793171T ATE490771T1 (de) 2003-10-24 2004-10-22 Therapeutisches mittel für keratokonjunktive erkrankungen
DK04793171.2T DK1679074T3 (da) 2003-10-24 2004-10-22 Terapeutisk middel til keratoconjunktive forstyrrelser
EP04793171A EP1679074B1 (en) 2003-10-24 2004-10-22 Therapeutic agent for keratoconjunctive disorder
CN2004800309819A CN1870997B (zh) 2003-10-24 2004-10-22 角膜结膜病变的治疗剂
PL04793171T PL1679074T3 (pl) 2003-10-24 2004-10-22 Środek terapeutyczny do leczenia chorób zapalnych rogówki i spojówki
KR1020067009936A KR101154175B1 (ko) 2003-10-24 2004-10-22 각결막 장해 치료제
DE602004030470T DE602004030470D1 (de) 2003-10-24 2004-10-22 Therapeutisches mittel für keratokonjunktive erkrankungen
US10/576,719 US7358255B2 (en) 2003-10-24 2004-10-22 Therapeutic agent for keratoconjunctival disorder

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003-364864 2003-10-24
JP2003364864 2003-10-24

Publications (2)

Publication Number Publication Date
WO2005039574A1 WO2005039574A1 (ja) 2005-05-06
WO2005039574A8 true WO2005039574A8 (ja) 2005-06-23

Family

ID=34510137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/016063 WO2005039574A1 (ja) 2003-10-24 2004-10-22 角結膜障害の治療剤

Country Status (16)

Country Link
US (1) US7358255B2 (ja)
EP (1) EP1679074B1 (ja)
JP (1) JP4217832B2 (ja)
KR (1) KR101154175B1 (ja)
CN (1) CN1870997B (ja)
AT (1) ATE490771T1 (ja)
CA (1) CA2543452C (ja)
CY (1) CY1111191T1 (ja)
DE (1) DE602004030470D1 (ja)
DK (1) DK1679074T3 (ja)
ES (1) ES2357801T3 (ja)
PL (1) PL1679074T3 (ja)
PT (1) PT1679074E (ja)
SI (1) SI1679074T1 (ja)
TW (1) TWI343256B (ja)
WO (1) WO2005039574A1 (ja)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060118520A (ko) * 2003-10-29 2006-11-23 산텐 세이야꾸 가부시키가이샤 각결막장해 치료제
WO2006064825A1 (ja) * 2004-12-14 2006-06-22 Santen Pharmaceutical Co., Ltd. ドライアイ治療剤
KR101409705B1 (ko) 2005-11-28 2014-07-14 센주 세이야꾸 가부시키가이샤 Ｐｐａｒ 아고니스트 함유 의약
LT2474545T (lt) 2005-12-13 2017-02-27 Incyte Holdings Corporation Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai
WO2008143254A1 (ja) * 2007-05-21 2008-11-27 Senju Pharmaceutical Co., Ltd. ＰＰＡＲδアゴニスト含有医薬
LT3070090T (lt) 2007-06-13 2019-06-25 Incyte Holdings Corporation Janus kinazės inhibitoriaus (r)-3-(4-(7h-pirol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropannitrilo druskų panaudojimas
KR20100137417A (ko) * 2008-02-25 2010-12-30 산텐 세이야꾸 가부시키가이샤 각막 상피 배리어 기능 항진제
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JP5775070B2 (ja) * 2009-05-22 2015-09-09 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体
MY161416A (en) 2009-05-22 2017-04-14 Incyte Holdings Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4yl)-1h-pyrazol-1-yl]octane-or heptane-nitrile as jak inhibitors
US9249145B2 (en) * 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
AR081315A1 (es) * 2010-03-10 2012-08-08 Incyte Corp Derivados heterociclicos de piperidin y pirimidin -4-il-azetidina, una forma cristalina de la sal del acido acetonitriladipico de un derivado pirimidinico, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades relacionadas con la inhibicion de jak-1, t
ME02445B (me) 2010-05-21 2016-09-20 Incyte Holdings Corp Topikalna formulacija za inhibiciju jak-a
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
AR083933A1 (es) 2010-11-19 2013-04-10 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
PE20140832A1 (es) 2011-06-20 2014-07-14 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
CA3178452A1 (en) 2012-11-15 2014-05-22 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
LT3489239T (lt) 2013-03-06 2022-03-10 Incyte Holdings Corporation Jak inhibitoriaus gamybos būdai ir tarpiniai junginiai
MY195091A (en) 2013-08-07 2023-01-10 Incyte Corp Sustained Release Dosage Forms for a JAK1 Inhibitor
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
WO2019152374A1 (en) 2018-01-30 2019-08-08 Incyte Corporation Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
MX2020010322A (es) 2018-03-30 2022-11-30 Incyte Corp Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0264586B1 (en) 1986-08-28 1991-04-03 Sanwa Kagaku Kenkyusho Co., Ltd. Hydantoin derivatives for treating complications of diabetes
JP3072227B2 (ja) * 1994-08-01 2000-07-31 株式会社クボタ 田植機の粉粒体供給装置
JP3603129B2 (ja) 1994-12-28 2004-12-22 株式会社三和化学研究所 糖尿病性角膜症の治療剤
IL118474A (en) 1995-06-01 2001-08-08 Sankyo Co Benzimideol derivatives and pharmaceutical preparations containing them
US6372750B2 (en) 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
US5885997A (en) 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6114526A (en) 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
HUP0301101A3 (en) 1996-12-31 2009-03-30 Reddy S Res Foundation Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
JPH11130675A (ja) * 1997-08-29 1999-05-18 Santen Pharmaceut Co Ltd クロマン誘導体含有点眼液
EP0909558A3 (en) * 1997-08-29 1999-10-27 Santen Pharmaceutical Co., Ltd. Chroman derivative containing ophthalmic solution
JP2001039976A (ja) * 1999-05-24 2001-02-13 Sankyo Co Ltd 縮合複素環化合物の塩酸塩
TWI284533B (en) * 1999-05-24 2007-08-01 Sankyo Co Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
JP2002220336A (ja) 2000-11-22 2002-08-09 Sankyo Co Ltd 縮合複素環化合物の塩酸塩を含有する糖尿病の予防薬、治療薬
JP4090013B2 (ja) 2000-12-26 2008-05-28 第一三共株式会社 利尿剤及びインスリン抵抗性改善剤を含有する医薬組成物
KR20060118520A (ko) 2003-10-29 2006-11-23 산텐 세이야꾸 가부시키가이샤 각결막장해 치료제

Also Published As

Publication number Publication date
EP1679074B1 (en) 2010-12-08
CN1870997B (zh) 2011-05-04
TW200518750A (en) 2005-06-16
KR101154175B1 (ko) 2012-06-14
CN1870997A (zh) 2006-11-29
JP2005145961A (ja) 2005-06-09
CY1111191T1 (el) 2015-06-11
PT1679074E (pt) 2011-03-03
EP1679074A4 (en) 2009-03-25
KR20060100440A (ko) 2006-09-20
ATE490771T1 (de) 2010-12-15
DK1679074T3 (da) 2011-03-21
TWI343256B (en) 2011-06-11
US7358255B2 (en) 2008-04-15
PL1679074T3 (pl) 2011-05-31
US20070060628A1 (en) 2007-03-15
WO2005039574A1 (ja) 2005-05-06
SI1679074T1 (sl) 2011-04-29
EP1679074A1 (en) 2006-07-12
ES2357801T3 (es) 2011-04-29
JP4217832B2 (ja) 2009-02-04
CA2543452C (en) 2012-03-13
CA2543452A1 (en) 2005-05-06
DE602004030470D1 (de) 2011-01-20

Similar Documents

Publication Publication Date Title
WO2005039574A8 (ja) 角結膜障害の治療剤
IL263314A (en) Use of Formula 2 receptor agonists for the treatment of ocular inflammatory diseases
HRP20141048T1 (hr) Spojevi, pripravci i metode
PE20110598A1 (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
ZA200606880B (en) Diaminopyrimidines as P2X3 and P2X2/3 antagonists
EP1078923A3 (en) Process for the preparation of benzothiophene derivatives
PE20081530A1 (es) Nuevos compuestos 617
PE20081532A1 (es) Compuestos novedosos
CA2634676A1 (en) Trisubstituted amine compounds as inhibitors of cholesteryl ester transfer protein cetp
ES2284856T3 (es) Derivados de quinolil propil piperidina, su preparacion y las composiciones que los contienen.
JP2006525364A5 (ja)
RU2008129723A (ru) Ингибиторы ccr9 активности
TW200700416A (en) 'n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites
US7589213B2 (en) Therapeutic substituted lactams
PE20070359A1 (es) Inhibidores de pirimidinilpirazol de aurora quinasas
TWI812944B (zh) 新穎苯基衍生物
MA25356A1 (fr) Polymorphe du sel de l'acide maleique 5-(4-(2-n-methyl-n(2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2,4-dione.
RU2367659C2 (ru) Гетероарильные производные в качестве активаторов рецепторов, активируемых пролифераторами пероксисом (ppar)
PE20050587A1 (es) Derivados de diazindol-dicarbonilo-piperazinilo como agentes antivirales
WO2009041565A1 (ja) キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含む角結膜障害の予防又は治療剤
FI963467A0 (fi) Tiatsolidiinidionijohdannaisia veren liikasokerisuuden vastaisina aineina
DE60212434D1 (de) Rosiglitazon-edisylate und ihre verwendung als antidiabetika
CA2537410A1 (en) Ophthalmic indazole comprising compositions for treating ocular hypertension
EA200300005A1 (ru) Соль тиазолидиндиона для лечения сахарного диабета
JP2004503538A5 (ja)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480030981.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WR Later publication of a revised version of an international search report
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007060628

Country of ref document: US

Ref document number: 2543452

Country of ref document: CA

Ref document number: 10576719

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004793171

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020067009936

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004793171

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067009936

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP

WWP Wipo information: published in national office

Ref document number: 10576719

Country of ref document: US